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INTRODUCTION
Management of chronic airway diseases: What can we learn from real-life data?
James D. Chalmers
Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
Chronic obstructive pulmonary disease (COPD), alpha-1 anti-
trypsin deficiency (AATD) and non-cystic fibrosis bronchiec-
tasis (hereafter referred to as bronchiectasis) are distinct but
related airway diseases:
 COPD is characterised by persistent and usually progres-
sive airflow limitation associatedwith an enhanced chronic
inflammatory response in the airways and lung to noxious
particles or gases (1). COPD is a clinical and physiological
diagnosis.
 AATD is a genetic disorder that causes defective produc-
tion of alpha-1-antitrypsin (AAT), leading to decreased
AAT activity in the blood and lungs and deposition of
excessive abnormal AAT protein in liver cells (2). AATD
is a laboratory diagnosis.
 Bronchiectasis is characterised by the presence of airway
dilatation and wall thickening on imaging (e.g. computed
tomography [CT]), with persistent or recurrent bronchial
infection (3). Bronchiectasis is a pathological or radiolog-
ical diagnosis.
Despite differences in the pathobiology of these condi-
tions, they share many of the same clinical features and many
of the same challenges. A definitive diagnosis is often com-
plicated by symptom non-specificity as illustrated in a case
study.
Case study
A 60-year-old female presented with breathlessness, cough
and sputum production. She had a history of childhood
asthma, but had been well for many years without chest
symptoms. Over the past 5 years, she had experienced wors-
ening respiratory symptoms, including two chest infections
in the past year, which required treatment with antibiotics.
The most recent infection had a sputum culture positive
for Haemophilus influenzae. Spirometry indicated a FEV1
of 47% predicted with no reversibility to salbutamol. The
patient was diagnosed with COPD and started on inhaled
bronchodilators and corticosteroids, in line with the clinical
picture.
But what if we were to factor in a smoking history of less than
5 pack-years? Non-smoking COPD or COPD associated with
minimal smoking is recognised, but should nevertheless prompt
the consideration of other diagnoses (4).
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What about AATD? AATDmay be associated with the onset
of COPD at a young age and with more severe COPD relative to
the amount smoked (2).
What about chronic asthma? The patient had not had symp-
toms for decades, and it is not clear whether childhood asthma
is relevant.
What about bronchiectasis? A diagnosis of bronchiectasis is
made more likely by the fact that most patients are female and
that average age at presentation is around 60 years (5). Cough,
sputum and airflow obstruction are common findings and a
large proportion of patients are initially diagnosed with COPD
before the correct diagnosis is made by CT scan (6).
A high-resolution CT scan confirmed bilateral bronchiec-
tasis with no emphysema. AAT levels were within the normal
range. The patient improved significantly with physiotherapy
and antibiotics.
A new approach to chronic airway diseases
Chronic airway diseases carry significant individual and soci-
etal burden. COPD is a major challenge to health care systems
worldwide due to its high prevalence and associated morbidity
and mortality (7). AATD is the primary diagnosis in approx-
imately 1% of COPD cases and is typically associated with a
more severe course; yet, the majority of cases go undetected
because screening tests in at-risk populations are underutilised
(8). Bronchiectasis is becoming increasingly prevalent, partic-
ularly in older age groups (50 years), and is associated with
substantially greater mortality compared with that in the gen-
eral population (6). Overlap between these three conditions
tends to worsen prognosis and has major implications for inves-
tigative and treatment strategies (9). Indeed, patients may have
bronchiectasis, COPD and AATD concurrently. Co-morbidities
are common and are the strongest predictors of mortality in
COPD. Recent data show that patients with bronchiectasis have
an average of four co-morbid diagnoses,many of which substan-
tially increase mortality (10).
The traditional ‘syndromic’ approach to medicine and to
respiratory medicine in particular is no longer sustainable in
the modern era of aging populations and multimorbidity. Per-
sonalised medicine indicates the need to recognise the unique
features of each individual’s disease and to target therapy to
those who will respond, while minimising treatment harms
(10). This begins by recognising that COPD and bronchiectasis
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are umbrella terms that include a wide range of Underlying
causes, associated co-morbidities and varying inflammatory
profiles (1,10,11).
This symposium, as part of the European Respiratory Soci-
ety’s International Congress 2016, provided an ideal forum
for respiratory disciplines to meet and share their experience
and expertise. There is much that the specialities can learn
from each other. AATD has led the way in establishing highly
successful patient registries (12,13). COPD is well advanced
in ‘phenotype’ identification and boasts an impressive collec-
tion of large and informative observational studies (14,15). In
the setting of chronic airway disease, well-conducted observa-
tional studies are often better equipped to answer clinical ques-
tions than randomised controlled trials (RCTs). Due to strict
inclusion and exclusion criteria (e.g. age, underlying diagnosis,
co-morbidities), RCTs are frequently not representative of the
populations they aim to treat (16). Moreover, patient recruit-
ment in rare diseases can be a challenge. At present, manage-
ment of COPD, AATD and bronchiectasis tends to be informed
primarily by clinical experience, although it is recognised that
development of best practice recommendations will require a
combination of good-quality RCTs and excellent observational
studies.
It is my pleasure to introduce these symposium proceed-
ings, which highlight the important contribution of real-life data
and registries to improving outcomes in patients with AATD,
bronchiectasis and COPD.
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